# Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

> **NCT02342613** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 32 (actual)

## Conditions studied

- Hematologic Malignancies
- Graft-Versus-Host Disease

## Interventions

- **BIOLOGICAL:** Activated PTCy-MILs

## Key facts

- **NCT ID:** NCT02342613
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-28
- **Primary completion:** 2023-11-29
- **Final completion:** 2024-03-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342613, "Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02342613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*